On Thursday, Qiagen NV (NASDAQ:QGEN)’s shares inclined 0.04% to $24.76.
Hitachi High-Technologies Corporation and QIAGEN N.V. (QGEN) have entered into a long-term strategic collaboration involving initiatives to deliver important advances in molecular testing.
Under terms of the agreement, both companies will bring their unique strengths to the collaboration: Hitachi High-Technologies is recognized as a leader in industrialized instrument development and manufacturing technologies, especially for life sciences and in-vitro diagnostics, while QIAGEN brings its leadership in molecular Sample to Insight solutions for use in both the life sciences and clinical diagnostics.
Initial projects for the partnership involve developing new automation systems based on PCR (polymerase chain reaction) and NGS (next-generation sequencing) technologies. Both parties agreed that the partnership could be expanded in the future to involve co-commercialization of products in specific geographic markets. Further terms of the partnership are confidential.
QIAGEN N.V. provides sample to insight solutions that transform biological samples into valuable molecular insights worldwide. It offers sample technologies to isolate, purify, and stabilize nucleic acids and proteins in plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, and library preparation for sequencing applications; and assay technologies to detect molecular targets.
Videocon d2h Limited American Depositary Shares (NASDAQ:VDTH)’s shares gained 1.74% to $12.89.
Videocon d2h Limited American Depositary Shares (VDTH) declared its financial results for the fiscal year ended March 31, 2015. The Company administration, led by Saurabh Dhoot, Executive Chairman, will hold two conference calls to talk about the results on June 4, 2015. This is the Company’s first earnings release since the listing of its American Depositary Shares on the NASDAQ on April 1, 2015.
Key highlights for Fiscal 2015:
- Revenue from operations grew 32.5% to INR 23.38 billion;
- Subscription revenue grew 38.3% to INR 20.58 billion;
- Adjusted EBITDA grew 55.3% to INR 6.09 billion (not taking into account one-off securities issue expenses and ESOP scheme impact of INR 135.17 million);
- Adjusted EBITDA margin expanded by 390 basis points to 26.1% despite content cost enhances;
- ARPU grew to INR 196 ahead of guidance, with Q4 ARPU at INR 202;
- Market leader in gross and net adds at 2.64 million and 1.74 million subscribers, respectively;
Videocon d2h Limited provides Direct-To-Home services under the Videocon d2h brand in India. The company distributes various television channels, and video and audio services to subscribers. As of June 30, 2014, it had 11.21 million gross subscribers. Videocon d2h Limited provides its services through a network of distributors and direct dealers, and sub-dealers.
At the end of Thursday’s trade, Cytori Therapeutics Inc (NASDAQ:CYTX)‘s shares dipped -0.70% to $0.624.
Cytori Therapeutics (CYTX) declared that preclinical and mechanistic data from its thermal injury study, performed with support from the Biomedical Advanced Research and Development Authority (BARDA), was published in the journal Burns, the official journal of the American Burn Association. The paper, entitled “Uncultured adipose-derived regenerative cells seeded in collagen scaffold improves dermal regeneration, enhancing early vascularization and structural organization following thermal burns” (Foubert P and coll. Published online: June 7, 2015 | DOI: 10.1016/j.burns.2015.05.004), is now accessible online [http://www.burnsjournal.com/article/S0305-4179(15)00132-1/abstract] and expands upon data presented earlier this year at the American Burn Association meeting.
This paper reports that seeding Cytori Cell Therapy™ onto a widely used dermal substitute led to improvement in a number of parameters of healing of full thickness burns. Specifically, histopathological assessment demonstrated that the average depth of tissue within the wound was raised by about 2-fold in animals treated with Cytori Cell Therapy. This was associated with an enhance in collagen deposition (1.7-fold), blood vessel density (1.5-fold), and mean vessel area (1.8-fold). Immunohistochemical analysis revealed an enhance in the number of vessels expressing α-SMA (a marker for mature blood vessels) in animals treated with Cytori’s Cell Therapy. Taken together, these results demonstrate that seeding Cytori Cell Therapy onto this scaffold promotes blood vessel maturation. Finally, the findings showed raised vascularity (1.5-fold) and cellularity (1.45-fold) of the dermal substitute itself.
Cytori Therapeutics, Inc., a biotechnology company, develops cell therapeutics for specific diseases and medical conditions. The company primarily provides Cytori Cell Therapy comprising of a heterogeneous population of specialized cells, counting stem cells for the treatment of patients with scleroderma hand dysfunction, orthopedic disorders, cardiovascular disease, urinary incontinence, and thermal burns combined with radiation injury.
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), ended its Thursday’s trading session with 1.32% gain, and closed at $14.57.
BioCryst Pharmaceuticals, Inc. (BCRX) and CSL Limited (ASX:CSL) (CSLLY) — BioCryst Pharmaceuticals, Inc., a pharmaceutical company focused on the development and commercialization of treatments for rare diseases, declared recently that it has licensed RAPIVAB (peramivir injection) for the treatment of influenza to CSL Limited, a global biopharmaceutical company.
RAPIVAB is an intravenous (I.V.) treatment indicated in the U.S. for acute uncomplicated influenza in adults 18 years and older. It is also presently licensed for use in Japan and Korea, and is the first and only approved intravenous influenza treatment in the world.
RAPIVAB will be commercialized by CSL’s partner, bioCSL, which specializes in influenza prevention through the supply of seasonal and pandemic influenza vaccine to global markets.
Under the terms of the agreement, bioCSL obtains worldwide rights to commercialize RAPIVAB, with the exception of Japan, Korea, Taiwan and Israel. BioCryst retains all rights to pursue pandemic stockpiling orders for RAPIVAB from the U.S. government, while bioCSL is responsible for government stockpiling outside the U.S.
BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. Its product candidates comprise peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza; BCX4161, an oral serine protease inhibitor, which is in Phase II clinical trial for hereditary angioedema (HAE); and BCX7353 and other second generation HAE compounds, which are oral serine protease inhibitors that are in preclinical trial for HAE.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
